[go: up one dir, main page]

WO1998036061A3 - Reducing fibrosis and/or scarring by inhibiting interleukin-6 receptor-mediated activity - Google Patents

Reducing fibrosis and/or scarring by inhibiting interleukin-6 receptor-mediated activity Download PDF

Info

Publication number
WO1998036061A3
WO1998036061A3 PCT/GB1998/000319 GB9800319W WO9836061A3 WO 1998036061 A3 WO1998036061 A3 WO 1998036061A3 GB 9800319 W GB9800319 W GB 9800319W WO 9836061 A3 WO9836061 A3 WO 9836061A3
Authority
WO
WIPO (PCT)
Prior art keywords
receptor
interleukin
scarring
mediated activity
inhibiting interleukin
Prior art date
Application number
PCT/GB1998/000319
Other languages
French (fr)
Other versions
WO1998036061A2 (en
Inventor
Mark William James Ferguson
Sharon O'kane
Original Assignee
Univ Manchester
Mark William James Ferguson
Kane Sharon O
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Manchester, Mark William James Ferguson, Kane Sharon O filed Critical Univ Manchester
Priority to AU62203/98A priority Critical patent/AU6220398A/en
Publication of WO1998036061A2 publication Critical patent/WO1998036061A2/en
Publication of WO1998036061A3 publication Critical patent/WO1998036061A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Environmental Sciences (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present application relates to the use of agents which inhibit Interleukin-6 receptor mediated activity for the treatment of wounds and/or fibrotic disorders such that fibrosis and/or scarring are reduced or prevented. Preferred agents for use in such treatments include Interleukin-6 neutralising antibodies, Interleukin-6 Receptor antagonists and inhibitors of Interleukin-6 Receptor signal transduction.
PCT/GB1998/000319 1997-02-13 1998-02-13 Reducing fibrosis and/or scarring by inhibiting interleukin-6 receptor-mediated activity WO1998036061A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU62203/98A AU6220398A (en) 1997-02-13 1998-02-13 Reducing fibrosis and/or scarring by inhibiting interleukin-6 receptor-mediated activity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9702944.1 1997-02-13
GBGB9702944.1A GB9702944D0 (en) 1997-02-13 1997-02-13 Reducing fibrosis

Publications (2)

Publication Number Publication Date
WO1998036061A2 WO1998036061A2 (en) 1998-08-20
WO1998036061A3 true WO1998036061A3 (en) 1998-11-12

Family

ID=10807559

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1998/000319 WO1998036061A2 (en) 1997-02-13 1998-02-13 Reducing fibrosis and/or scarring by inhibiting interleukin-6 receptor-mediated activity

Country Status (3)

Country Link
AU (1) AU6220398A (en)
GB (1) GB9702944D0 (en)
WO (1) WO1998036061A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8945558B2 (en) 2005-10-21 2015-02-03 Chugai Seiyaku Kabushiki Kaisha Methods for treating myocardial infarction comprising administering an IL-6 inhibitor

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9818278D0 (en) * 1998-08-22 1998-10-14 Smith & Nephew Compositions
CA2349762C (en) 1998-11-13 2013-12-24 Immunex Corporation Human tslp dna and polypeptides
ATE360696T1 (en) * 2000-06-30 2007-05-15 Zymogenetics Inc INTERFERON-LIKE PROTEIN ZCYTO21
ES2422879T3 (en) 2001-07-23 2013-09-16 Immunex Corporation Modified human thymic stromal lymphopoietin
EP1572103A4 (en) * 2002-11-15 2008-02-13 Centocor Inc Anti-angiogenic uses of il-6 antagonists
WO2005028514A1 (en) * 2003-09-22 2005-03-31 Biovation Gmbh & Co. Kg. Use of a compound for reducing the biological effectiveness of il-6
US20060171943A1 (en) * 2005-02-01 2006-08-03 Amgen Inc. Compositions and methods of treating fibrotic disorders
CA2625773C (en) 2005-10-14 2015-05-12 Fukuoka University Inhibition of interleukin-6 (il-6) receptor promotes pancreatic islet transplantation
AR057582A1 (en) 2005-11-15 2007-12-05 Nat Hospital Organization AGENTS TO DELETE INDUCTION OF CYTOTOXIC T LYMPHOCYTES
AR059213A1 (en) 2006-01-27 2008-03-19 Univ Keio THERAPEUTIC AGENTS FOR DISEASES INVOLVING COROIDAL NEOVASCULARIZATION
CN101495146B (en) 2006-04-07 2012-10-17 国立大学法人大阪大学 muscle regeneration enhancer
EP2064241B1 (en) 2006-08-03 2015-10-07 Vaccinex, Inc. Anti-il-6 monoclonal antibodies and uses thereof
BRPI0806812B8 (en) 2007-01-23 2021-09-14 Chugai Pharmaceutical Co Ltd Agent for suppressing chronic rejection reaction and use of an il-6 inhibitor
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
CA2728243C (en) 2008-06-05 2020-03-10 National Cancer Center Il-6 inhibitor for suppressing neuroinvasion in pancreatic cancer
DK2578231T3 (en) 2010-05-28 2022-12-12 Chugai Pharmaceutical Co Ltd ANTI-TUMOR T-CELL RESPONSE AMPLIFIER
EP2802572B1 (en) 2012-01-13 2018-11-07 President and Fellows of Harvard College Halofuginol derivatives and their use in cosmetic and pharmaceutical compositions
GB201522186D0 (en) * 2015-12-16 2016-01-27 Singapore Health Services Pte Ltd And Nat University Of Singapore The Treatment of fibrosis
EP3555131B1 (en) 2016-12-16 2024-07-31 Singapore Health Services Pte Ltd Il-11 antibodies
GB201621439D0 (en) 2016-12-16 2017-02-01 Singapore Health Services Pte Ltd And Nat Univ Of Singapore IL-11Ra Antibodies
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
JP2020528054A (en) * 2017-07-19 2020-09-17 オークランド ユニサービシズ リミテッド Cytokine modulation
KR102771895B1 (en) 2017-10-20 2025-02-21 가꼬우호우징 효고 이카다이가쿠 Pharmaceutical composition for inhibiting postoperative adhesion containing anti-IL-6 receptor antibody
WO2019237125A1 (en) 2018-06-08 2019-12-12 The General Hospital Corporation Inhibitors of prolyl-trna-synthetase
BR112021014105A2 (en) 2019-01-21 2021-10-13 Singapore Health Services Pte Ltd AGENT CAPABLE OF INHIBITING INTERLEUKIN 11 MEDIATED SIGNALING, USE THEREOF AND METHOD FOR TREATMENT OR PREVENTION OF HEPATOTOXICITY AND/OR A DISORDER, DISEASE OR CONDITION ASSOCIATED WITH HEPATOTOXICITY
IL311043A (en) 2021-08-30 2024-04-01 Lassen Therapeutics 1 Inc Anti-IL---11RA antibodies

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992008474A2 (en) * 1990-11-20 1992-05-29 The National Heart & Lung Institute Treatment of lung diseases
EP0617126A2 (en) * 1993-02-17 1994-09-28 Ajinomoto Co., Inc. Polypeptide capable of inhibiting the binding bewteen human IL-6 and its receptor
WO1994025036A1 (en) * 1993-04-30 1994-11-10 Chugai Seiyaku Kabushiki Kaisha Expression inhibitor containing antisense oligonucleotide derivative against human interleukin-6 receptor
WO1996012503A1 (en) * 1994-10-21 1996-05-02 Chugai Seiyaku Kabushiki Kaisha Remedy for diseases caused by il-6 production
WO1996018648A1 (en) * 1994-12-14 1996-06-20 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Superagonists and antagonists of h il-6, and 3d modelling method for their selection
WO1997048728A1 (en) * 1996-06-20 1997-12-24 Koster, Henk, Wilhelmus Il-6 and il-6-receptor derived peptides having il-6 antagonistic or agonistic activity

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992008474A2 (en) * 1990-11-20 1992-05-29 The National Heart & Lung Institute Treatment of lung diseases
EP0617126A2 (en) * 1993-02-17 1994-09-28 Ajinomoto Co., Inc. Polypeptide capable of inhibiting the binding bewteen human IL-6 and its receptor
WO1994025036A1 (en) * 1993-04-30 1994-11-10 Chugai Seiyaku Kabushiki Kaisha Expression inhibitor containing antisense oligonucleotide derivative against human interleukin-6 receptor
WO1996012503A1 (en) * 1994-10-21 1996-05-02 Chugai Seiyaku Kabushiki Kaisha Remedy for diseases caused by il-6 production
WO1996018648A1 (en) * 1994-12-14 1996-06-20 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Superagonists and antagonists of h il-6, and 3d modelling method for their selection
WO1997048728A1 (en) * 1996-06-20 1997-12-24 Koster, Henk, Wilhelmus Il-6 and il-6-receptor derived peptides having il-6 antagonistic or agonistic activity

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
R. SAVINO ET AL.: "Generation of interleukin-6 receptor antagonists by molecular-modeling guided mutagenesis of residues important for gp130 activation.", THE EMBO JOURNAL, vol. 13, no. 6, 15 March 1994 (1994-03-15), Oxford, GB, pages 1357 - 1367, XP000565719 *
T. TAGA ET AL.: "Functional inhibition of hematopoietic and neurotrophic cytokines by blocking the interleukin 6 signal transducer gp130.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE USA, vol. 89, no. 22, November 1992 (1992-11-01), Washinton, DC, USA, pages 10998 - 11001, XP002075302 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8945558B2 (en) 2005-10-21 2015-02-03 Chugai Seiyaku Kabushiki Kaisha Methods for treating myocardial infarction comprising administering an IL-6 inhibitor

Also Published As

Publication number Publication date
WO1998036061A2 (en) 1998-08-20
AU6220398A (en) 1998-09-08
GB9702944D0 (en) 1997-04-02

Similar Documents

Publication Publication Date Title
WO1998036061A3 (en) Reducing fibrosis and/or scarring by inhibiting interleukin-6 receptor-mediated activity
HK1038755A1 (en) Antagonists of tweak and of tweak receptor and their use to treat immunological disorders
WO2001078702A3 (en) Methods and compositions for modulating alpha adrenergic receptor activity
WO2000006085A3 (en) Compounds and methods
WO2003057837A3 (en) Methods for using anti-muc18 antibodies
WO2002022153A3 (en) Use of a polypeptide comprising the extracellular domains of il-20rb for the treatment of inflammation
EP1425277B8 (en) Urea-compounds active as vanilloid receptor antagonists for the treatment of pain
IL142921A0 (en) USES FOR Eph RECEPTOR ANTAGONISTS AND AGONISTS TO TREAT VASCULAR DISORDERS
WO2001015678A3 (en) Topical use of kappa opioid agonists to treat otic pain
WO2003032912A3 (en) Treatment of cns disorders using cns target modulators
AU6530600A (en) Use of neurotoxin for treating cardiac muscle disorders
AU2604301A (en) Tnf inhibitors for the treatment of neurological, retinal and muscular disorders
WO2002072536A8 (en) Urea derivatives having vanilloid receptor (vr1) antagonist activity
AU2002361811A1 (en) 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
WO2003045434A3 (en) Endothelin antagonists ina method and composition for potentiating an opiate analgesic
WO2001078703A3 (en) Methods and compositions for modulating alpha adrenergic receptor activity
AU1423795A (en) Treatment of normotensive glaucoma with angiotensin ii antagonists
WO2005030187A3 (en) Iloprost in combination therapies for the treatment of pulmonary arterial hypertension
WO2004084943A8 (en) Use of antagonists of ghrelin or ghrelin receptor to treat intestinal inflammation
EP2286817A3 (en) Method of treating functional bowel disorders
WO1997010824A8 (en) Use of 5ht1b receptor antagonist for the treatment of vascular disease
CA2392804A1 (en) Combined agents for treatment of glaucoma
HK1044483A1 (en) Il-8 receptor antagonists
WO2002017895A3 (en) Use of an aldosterone receptor antagonist to improve cognitive function
WO2000002551A3 (en) Methods and compounds for treating depression

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998535442

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase